Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
University of California, San Francisco
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Intergroupe Francophone de Cancerologie Thoracique
University of Miami
European Institute of Oncology
Mario Negri Institute for Pharmacological Research
Spanish Breast Cancer Research Group
H. Lee Moffitt Cancer Center and Research Institute
SOLTI Breast Cancer Research Group
St. Jude Children's Research Hospital
The Netherlands Cancer Institute
The Cleveland Clinic
Dana-Farber Cancer Institute
Sun Yat-sen University
Memorial Sloan Kettering Cancer Center
Seoul National University Hospital
Fudan University
Insel Gruppe AG, University Hospital Bern
UNICANCER
Guangdong Provincial People's Hospital
Peking University Shenzhen Hospital
University of Rochester
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Spanish Lung Cancer Group
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Memorial Sloan Kettering Cancer Center
University of Nebraska
The First Affiliated Hospital with Nanjing Medical University
ARCAGY/ GINECO GROUP
European Institute of Oncology
AIO-Studien-gGmbH
National Cancer Institute, Naples
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Second Affiliated Hospital of Soochow University
Peking University First Hospital
Odense University Hospital
University Hospital, Brest
Sun Yat-sen University
Fudan University
Fudan University
Fudan University
Tianjin Medical University Cancer Institute and Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Wales Cancer Trials Unit
Shandong Cancer Hospital and Institute